Management of symptomatic benign prostatic hyperplasia--today

Area of Science:

• Urology
• Andrology

Background:

• Symptomatic benign prostatic hyperplasia (BPH) is a prevalent condition causing lower urinary tract symptoms (LUTS) in over 50% of men aged fifty and older.
• Untreated BPH can lead to disease progression, necessitating interventions.

Purpose of the Study:

• To identify predictive baseline parameters for offering therapy to men with BPH.
• To evaluate the efficacy of combination therapy (5-alpha reductase inhibitor [5-ARI] and alpha blocker) in preventing BPH progression and surgical intervention.

Main Methods:

• Utilizing baseline parameters including International Prostate Symptom Score (IPSS), prostate volume, prostate-specific antigen (PSA), and degree of bother for patient stratification.
• Investigating the role and duration of combination therapy for BPH management.

Main Results:

• Establishing criteria based on IPSS, prostate volume, PSA, and bother to guide therapeutic decisions.
• Demonstrating that combination therapy may offer superior outcomes in preventing BPH progression compared to monotherapy.

Conclusions:

• Predictive baseline parameters can aid in identifying men who will benefit from BPH therapy.
• Combination therapy with a 5-ARI and an alpha blocker shows promise in preventing BPH progression and reducing the need for surgery, though optimal utilization requires further consideration.